Last update 23 Jan 2025

Buspirone Hydrochloride/Melatonin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Buspirone/melatonin, BCI-024/BCI-049, BCI-952
Target
5-HT1A receptor x D2 receptor x Melatonin receptor
Mechanism
5-HT1A receptor partial agonists(Serotonin 1a (5-HT1a) receptor partial agonists), D2 receptor antagonists(Dopamine D2 receptor antagonists), Melatonin receptor agonists
Therapeutic Areas
Nervous System Diseases
Active Indication-
Inactive Indication
Depressive Disorder, MajorMajor depressive disorder, moderate (MDD)
Originator Organization
BrainCells, Inc.BrainCells, Inc.
Active Organization-
Inactive Organization
BrainCells, Inc.BrainCells, Inc.
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC13H16N2O2
InChIKeyDRLFMBDRBRZALE-UHFFFAOYSA-N
CAS Registry73-31-4
View All Structures (2)

Related

2
Clinical Trials associated with Buspirone Hydrochloride/Melatonin
NL-OMON36120
/ CompletedNot Applicable
A PHASE I, OPEN-LABEL, FIXED-SEQUENCE, THREE-PERIOD CROSSOVER TRIAL TO EVALUATE THE PHARMACOKINETICS OF TWO DIFFERENT TABLET FORMULATIONS OF BCI 952 COMPARED TO THE OVER-ENCAPSULATED BCI-952 PRODUCT COMPONENTS IN HEALTHY MALE SUBJECTS - BCI-952 three-period crossover bioequivalence study
NCT00731653
/ CompletedPhase 2IIT
An Open-Label Extension Study to Assess the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder
100 Clinical Results associated with Buspirone Hydrochloride/Melatonin
Login to view more data
100 Translational Medicine associated with Buspirone Hydrochloride/Melatonin
Login to view more data
100 Patents (Medical) associated with Buspirone Hydrochloride/Melatonin
Login to view more data
100 Deals associated with Buspirone Hydrochloride/Melatonin
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Depressive Disorder, MajorPhase 2
US
BrainCells, Inc.BrainCells, Inc.
01 Jul 2008
Major depressive disorder, moderate (MDD)Phase 2
US
BrainCells, Inc.BrainCells, Inc.
01 Jul 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT00731653 (CTgov)
Phase 2
Major depressive disorder, moderate (MDD) | Depressive Disorder, Major
81
Melatonin+Buspirone
gzagsyazaa(attllrjxto) = yimzkyurje frxqxtuzwy (xfasuzueij, puoehiogsa - ydzqdazemj)
View more
-
17 Dec 2013
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free